Prof Sherene Loi
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
739 Scholarly works
41 Projects
HIGHLIGHTS
2026
Journal article
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer
DOI: 10.1016/j.esmoop.2026.1077352026
Journal article
439P Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 metastatic breast cancer (mBC) and active brain metastases (BM): Final analysis of DESTINY-Breast07 (DB-07)
DOI: 10.1016/j.esmoop.2026.1074622026
Research grants (ARC, NHMRC, MRFF)
Innovating in Breast Cancer Immunology Treatment and Prevention
2022
Journal article
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
DOI: 10.1038/s43018-022-00413-x2021
Journal article
Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
DOI: 10.1093/jnci/djab1112018
Research Grant
Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
2018
Research grants (other domestic)
2018 NBCF Endowed Chair Program
RECENT SCHOLARLY WORKS
2026
Journal article
12P Circulating tumor DNA (ctDNA) and serum thymidine kinase activity (sTKa) in patients with endocrine resistant MBC treated with palbociclib and fulvestrant (P F) in the PYTHIA trial
DOI: 10.1016/j.esmoop.2026.1069772026
Journal article
420RO Efficacy of inavolisib (INAVO) palbociclib (PALBO) fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) with and without hyperglycaemia (HG) in the phase III INAVO120 trial
DOI: 10.1016/j.esmoop.2026.1074432026
Journal article
230P Health-related quality of life (HRQoL) in patients (pts) with HR /HER2− early breast cancer (EBC) receiving adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone: NATALEE 5-y outcomes
DOI: 10.1016/j.esmoop.2026.1071842026
Journal article
275P 15-year incidence of invasive local, regional or contralateral events as first subsequent breast cancer event among HR premenopausal patients in SOFT and TEXT
DOI: 10.1016/j.esmoop.2026.1072272026
Journal article
17P International survey of TIL assessment in breast cancer: Current use, clinical integration, and implementation barriers
DOI: 10.1016/j.esmoop.2026.1069822026
Journal article
33P Deep learning – based tumor-infiltrating lymphocyte (TIL) profiling in the monarchE study
DOI: 10.1016/j.esmoop.2026.1069942026
Journal article
Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma : A report on behalf of the International Immuno-Oncology Biomarker Working Group
DOI: 10.1111/his.700892026
Journal article
LBA2 A window-of-opportunity (WOO) trial of giredestrant /- LHRH analogue vs anastrozole LHRHa in premenopausal patients with ER /HER2- early breast cancer: PREcoopERA
DOI: 10.1016/j.esmoop.2026.107277